The Efficacy of Shenmai Injection Combined with Entecavir in Treating Patients with Hepatitis B-Related Compensated Cirrhosis
[Objective]To explore the efficacy of Shenmai Injection combined with Entecavir in the treatment of pa-tients with hepatitis B-related compensated cirrhosis and its impact on immunological indicators.[Methods]Seventy-eight patients with hepatitis B-related compensated cirrhosis were randomly divided into an observation group and a control group,each consisting of 39 patients.The control group received Entecavir treatment,while the observation group was treated with Shenmai Injection combination with Entecavir.The efficacy of the treatments was compared between the two groups,along with liver fibrosis indicators[Type Ⅳ Collagen(Ⅳ-C),Laminin(LN)],liver function indicators[Aspartate Aminotransferase(AST),Alanine Aminotransferase(ALT)],immunological indicators before and after treatment,and the incidence of adverse reactions.[Results]The total effective rate in the observation group was 94.87％(37/39),which was higher than the 76.92％(30/39)in the control group,with a statistically significant difference(P＜0.05).After treatment,the levels of Ⅳ-C,LN,AST,and ALT in both groups were reduced compared to before treatment(P＜0.05),and the levels in the observation group were lower than those in the control group(P＜0.05).The levels of both Th17/Treg and CD8+in two groups decreased after treatment compared to before treatment(P＜0.05),and the Th17/Treg and CD8+levels in the observation group were lower than those in the control group(P＜0.05).After treatment,the level of CD4+increased in both groups(P＜0.05),while CD4+level in the observation group was higher than that in the control group(P＜0.05).The overall incidence of adverse reactions was not significantly different between the two groups(P＞0.05).[Conclusion]The combination of Shenmai Injection with Entecavir is significantly effective in treating patients with hepatitis B-related compensated cirrhosis.It can improve liver function and it is safe and reliable,making it worthy of clinical application and promotion.
万方数据
维普
